Alembic Pharma gets USFDA nod for stroke and blood clots drug

The drug major said that it has received a final approval from the US drug regulator for Dabigatran Etexilate Capsules in strengths of 75 mg and 150 mg, and a tentative approval for the 110 mg variant.